The SARS-CoV-2 Pandemic: What are the Limits and Promises of Technical Mitigation Instruments Available to Humanity?-Reference-Cited by-同舟云学术

The SARS-CoV-2 Pandemic: What are the Limits and Promises of Technical Mitigation Instruments Available to Humanity?

Published:2023-03-21 Issue: Volume:36 Page:1439-1445
ISSN:2791-0210
Container-title:Highlights in Science, Engineering and Technology
language:
Short-container-title:HSET

Author:

Huang Yu-An

Abstract

The SARS-CoV-2 pandemic has brought unprecedented attention to the effectiveness and reliability of technical containment tools. Given the high mobility and frequent transcontinental travel in the modern world, we are in uncharted territory with the catastrophic effects of the COVID -19 pandemic and many more to come. Therefore, prevention, detection, and treatment tools are of utmost importance. These tools include diagnostics, drugs, and vaccines. The inequity caused by these medical tools will be briefly presented, but the main focus of the essay will be on the importance of the promise and limitations of these tools. Public health countermeasures and scientific countermeasures go hand in hand in combating the SARS-CoV-2 pandemic. To successfully combat COVID -19 and the next Disease X pandemic, the effectiveness and accuracy of technical tools to contain the virus are critical parameters.

Publisher

Darcy & Roy Press Co. Ltd.

Reference20 articles.

1. Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., Simons, D., Blomquist, P. B., Zaidi, A., Nash, S., Iwani Binti Abdul Aziz, N., Thelwall, S., Dabrera, G., Myers, R., Amirthalingam, G., … Lopez Bernal, J. (2022). Covid-19 vaccine effectiveness against the Omicron (b.1.1.529) variant. New England Journal of Medicine, 386 (16), 1532 – 1546. https://doi.org/10.1056/nejmoa2119451.

2. Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., Lopez de Castilla, D., Finberg, R. W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T. F., Paredes, R., Sweeney, D. A., Short, W. R., … Lane, H. C. (2020). Remdesivir for the treatment of covid-19 — final report. New England Journal of Medicine, 383 (19), 1813 – 1826. https: //doi.org/10.1056/nejmoa2007764.

3. Binagwaho, A., Mathewos, K., & Davis, S. (2021). Time for the ethical management of covid-19 vaccines. The Lancet Global Health, 9 (8). https: //doi.org/10.1016/s2214-109x (21) 00180 - 7.

4. Bollyky, T. J., Gostin, L. O., & Hamburg, M. A. (2020). The equitable distribution of Covid-19 Therapeutics and vaccines. JAMA, 323(24), 2462. https: //doi.org/10.1001/jama.2020.6641.

5. Caldwell, J. M., Le, X., McIntosh, L., Meehan, M. T., Ogunlade, S., Ragonnet, R., O'Neill, G. K., Trauer, J. M., & McBryde, E. S. (2021). Vaccines and variants: Modelling insights into emerging issues in COVID-19 epidemiology. Paediatric Respiratory Reviews, 39, 32–39. https://doi.org/10.1016/j.prrv.2021.07.002.